Steffi Busch
German Society of Surgery(DE)Angiologica (Italy)(IT)
Publications by Year
Research Areas
Nausea and vomiting management, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Pregnancy and Medication Impact, HER2/EGFR in Cancer Research
Most-Cited Works
- → Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial(2023)39 cited
- → Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy(2021)12 cited
- → Treatment patterns, health care resource use and outcomes in metastatic triple-negative breast cancer in Germany: retrospective chart review study (OBTAIN)(2019)9 cited
- → Discussion of ABC7 Consensus and German Recommendations(2024)5 cited
- → The Endocrine Treatment Landscape for Patients with HR+ HER2− Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy – A Real-World Analysis(2023)4 cited
- → ABC7 Consensus: Assessment by a German Group of Experts(2024)2 cited
- → Abstract P1-11-10: Efficacy of NEPA as antiemetic prophylaxis in breast cancer patients receiving highly or moderately emetogenic chemotherapy – Interim results of a German prospective, non-interventional study(2019)1 cited
- → Effektive antiemetische Prophylaxe mit Palonosetron bei Mammakarzinompatientinnen mit adjuvanter anthrazyklinhaltiger Chemotherapie(2012)
- → 2022-RA-367-ESGO Rucaparib in clinical practice – what are the elements of patient adherence?(2022)
- → Abstract P2-12-02: Quality of life data of breast cancer patients receiving a fixed combination of netupitant/palonosetron (NEPA) for prevention of chemotherapy-induced nausea and vomiting - A real life study(2020)